MVT-601A-006 MOXIE

Recruiting

99 years and younger

All

Phase N/A

1 Location

Brief description of study

The primary objective of this study is to characterize changes in bone mineral density (BMD) during continuous treatment with relugolix combination tablet (relugolix 40 mg/estradiol [E2] 1 mg/norethindrone acetate [NETA] 0.5 mg) for up to 48 months (4 years) in two cohorts: (1) premenopausal women with heavy menstrual bleeding associated with uterine leiomyomas (fibroids) and (2) premenopausal women with moderate to severe pain associated with endometriosis.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
Medical Research
Age: - 99 Years
Gender: All

TBD

Updated on 15 May 2024. Study ID: 855277

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).